155 related articles for article (PubMed ID: 12496449)
1. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice.
Ostlie N; Milani M; Wang W; Okita D; Conti-Fine BM
J Immunol; 2003 Jan; 170(1):604-12. PubMed ID: 12496449
[TBL] [Abstract][Full Text] [Related]
2. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
[TBL] [Abstract][Full Text] [Related]
3. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
4. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.
Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
J Clin Invest; 1997 Dec; 100(12):3027-35. PubMed ID: 9399949
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis.
Ostlie NS; Karachunski PI; Wang W; Monfardini C; Kronenberg M; Conti-Fine BM
J Immunol; 2001 Apr; 166(8):4853-62. PubMed ID: 11290761
[TBL] [Abstract][Full Text] [Related]
6. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
Deng C; Goluszko E; Christadoss P
J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
[TBL] [Abstract][Full Text] [Related]
7. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.
Wang W; Ostlie NS; Conti-Fine BM; Milani M
J Immunol; 2004 Jan; 172(1):97-103. PubMed ID: 14688314
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice.
Karachunski PI; Ostlie N; Bellone M; Infante AJ; Conti-Fine BM
Scand J Immunol; 1995 Aug; 42(2):215-25. PubMed ID: 7631155
[TBL] [Abstract][Full Text] [Related]
9. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Maruta T; Oshima M; Mosier DR; Atassi MZ
Autoimmunity; 2017 Aug; 50(5):293-305. PubMed ID: 28548588
[TBL] [Abstract][Full Text] [Related]
10. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis.
Poussin MA; Tüzün E; Goluszko E; Scott BG; Yang H; Franco JU; Christadoss P
J Immunol; 2003 Apr; 170(8):4389-96. PubMed ID: 12682276
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
Lobito AA; Yang B; Lopes MF; Miagkov A; Adams RN; Palardy GR; Johnson MM; McFarland HI; Recher M; Drachman DB; Lenardo MJ
Eur J Immunol; 2002 Jul; 32(7):2055-67. PubMed ID: 12115627
[TBL] [Abstract][Full Text] [Related]
12. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.
Oshima M; Yokoi T; Deitiker P; Atassi MZ
Autoimmunity; 1998; 27(2):79-90. PubMed ID: 9583739
[TBL] [Abstract][Full Text] [Related]
13. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
14. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis.
Milani M; Ostlie N; Wu H; Wang W; Conti-Fine BM
J Neuroimmunol; 2006 Oct; 179(1-2):152-62. PubMed ID: 16945426
[TBL] [Abstract][Full Text] [Related]
16. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci.
Stassen MH; Meng F; Melgert E; Machiels BM; Im SH; Fuchs S; Gerritsen AF; van Dijk MA; van de Winkel JG; De Baets MH
J Neuroimmunol; 2003 Feb; 135(1-2):56-61. PubMed ID: 12576224
[TBL] [Abstract][Full Text] [Related]
17. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor.
Rosenberg JS; Oshima M; Atassi MZ
J Immunol; 1996 Oct; 157(7):3192-9. PubMed ID: 8816433
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis.
Yang H; Kala M; Scott BG; Goluszko E; Chapman HA; Christadoss P
J Immunol; 2005 Feb; 174(3):1729-37. PubMed ID: 15661938
[TBL] [Abstract][Full Text] [Related]
19. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
Schaffert H; Pelz A; Saxena A; Losen M; Meisel A; Thiel A; Kohler S
Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
[TBL] [Abstract][Full Text] [Related]
20. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
